Category REGULATORY

AAD 2026

AAD 2026: Almirall Showcases New Clinical and Real-World Data on Atopic Dermatitis, Psoriasis, Actinic Keratosis, and Acne

AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne Almirall S.A. a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio…

Read MoreAAD 2026: Almirall Showcases New Clinical and Real-World Data on Atopic Dermatitis, Psoriasis, Actinic Keratosis, and Acne
Turn Therapeutics

Turn Therapeutics raises up to $25 million in funding from Avenue Capital Group.

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group Turn Therapeutics, Inc. a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue…

Read MoreTurn Therapeutics raises up to $25 million in funding from Avenue Capital Group.
National Hospital

GenSight Biologics and 15–20 National Hospital begin first GS010/LUMEVOQ® treatments under France’s AAC program.

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME…

Read MoreGenSight Biologics and 15–20 National Hospital begin first GS010/LUMEVOQ® treatments under France’s AAC program.
Coya Therapeutics

Coya Therapeutics reports study linking T-cell dysfunction and inflammation in frontotemporal dementia, supporting COYA 302.

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a…

Read MoreCoya Therapeutics reports study linking T-cell dysfunction and inflammation in frontotemporal dementia, supporting COYA 302.

Veristat Boosts EU Regulatory & Clinical Support for Chinese Pharma and Device Firms

Veristat Expands Regulatory and Clinical Trial Support for Chinese Pharmaceutical and Medical Device Companies Entering Global Markets Veristat, a global contract research organization (CRO) and consulting firm known for its expertise in complex clinical trials, has announced the expansion of…

Read MoreVeristat Boosts EU Regulatory & Clinical Support for Chinese Pharma and Device Firms